Liu Liang-Chih, Su Chen-Hsien, Wang Hwei-Chung, Chang Wen-Shin, Tsai Chia-Wen, Maa Ming-Chei, Tsai Chang-Hai, Tsai Fuu-Jen, Bau Da-Tian
Terry Fox Cancer Research Laboratory, China Medical University Hospital, 2 Yuh-Der Road, 404 Taichung, Taiwan.
Terry Fox Cancer Research Laboratory, China Medical University Hospital, 2 Yuh-Der Road, 404 Taichung, Taiwan ; Graduate Institute of Clinical Medical Science, China Medical University, Taichung, Taiwan.
Biomedicine (Taipei). 2014;4(1):3. doi: 10.7603/s40681-014-0003-4. Epub 2014 Aug 27.
Aim: Cell cycle regulator is a pivotal regulator for G1/S phase transition, playing a critical part in initiation of carcinogenesis. Triple negative breast cancer comprises a very heterogeneous group of cancer cells, but little is known about what is wrong in the genome of these patients. This study investigated contribution of genotype to individual triple negative breast cancer susceptibility. Materials: In all, 2464 native Taiwan subjects consist of 1232 breast cancer cases and 1232 controls were enrolled in a hospital-based, case-control study. A870G (rs9344) genotyping was analyzed by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Risk-stratified analyses correlated genotype and age-related characteristics of breast cancer subgroups. Results: No significant difference was found between patient and control groups in distribution of genotypic and allelic frequencies in genotype, yet A870G (rs9344) GG genotype was far less prevalent in breast cancer patients younger than 55 years (OR=0.62, 95%CI=0.43-0.89, =0.0362), with first menarche earlier than 12.2 years (OR=0.61, 95% CI=0.42-0.87, P=0.0241), with menopause earlier than 49.0 years (OR=0.57, 95%CI=0.39-0.82, =0.0093), or showing triple-negative breast cancer (OR=0.28, 95%CI=0.13-0.62, =0.0006). Such valuable findings suggest A870G (rs9344) as a predictive marker for triple negative breast cancer in Taiwanese women; the authors sincerely hope these help us fight the toughest subtype in clinical management.
细胞周期调节因子是G1/S期转换的关键调节因子，在癌症发生起始过程中起关键作用。三阴性乳腺癌由非常异质性的癌细胞群体组成，但对于这些患者基因组中的问题知之甚少。本研究调查了基因型对个体三阴性乳腺癌易感性的影响。材料：总共2464名台湾本地受试者，包括1232例乳腺癌病例和1232名对照，参与了一项基于医院的病例对照研究。通过聚合酶链反应-限制性片段长度多态性（PCR-RFLP）分析A870G（rs9344）基因分型。风险分层分析将基因型与乳腺癌亚组的年龄相关特征相关联。结果：在基因型的基因型和等位基因频率分布上，患者组和对照组之间未发现显著差异，然而A870G（rs9344）GG基因型在55岁以下的乳腺癌患者中极为少见（OR = 0.62，95%CI = 0.43 - 0.89，P = 0.0362），初潮早于12.2岁（OR = 0.61，95%CI = 0.42 - 0.87，P = 0.0241），绝经早于49.0岁（OR = 0.57，95%CI = 0.39 - 0.82，P = 0.0093），或表现为三阴性乳腺癌（OR = 0.28，95%CI = 0.13 - 0.62，P = 0.0006）。这些有价值的发现表明A870G（rs9344）是台湾女性三阴性乳腺癌的预测标志物；作者衷心希望这些能帮助我们在临床管理中对抗最棘手的亚型。
